News

Combination treatment with Velcade (bortezomib) and Thalomid (thalidomide) may significantly improve survival of multiple myeloma patients who received a stem cell transplant, according to recent…

Cellectar Biosciences has been granted a U.S. patent for the method of use for the compounds CLR 131 and CLR 125 in the treatment of…

Patients with bone metastasis due to multiple myeloma, breast or prostate cancer, who received zoledronic acid every 12 weeks for two years, did not have increased risk of skeletal-related events…

The Kerry and Simone Vickar Family Foundation has committed $2 million to establish an endowed chair in their name at the Levine Cancer…

A new type of dendritic cell-based immunotherapy triggered an immune response in the majority of patients in a small Phase 1 trial (NCT02248402) of…

Changes in gene activity in the DNA of multiple myeloma cells can lead to the progression of the disease by shutting down the expression of…

Janssen Biotech and Bristol-Myers Squibb will collaborate in a clinical trial program to evaluate the combination of Darzalex (daratumumab) and Opdivo (nivolumab) in multiple myeloma…

Adding the proteasome inhibitor Velcade (bortezomib) to the standard therapy of Revlimid (lenalidomide) and dexamethasone — a triple combo therapy — significantly extends progression-free survival and…

Researchers have discovered a mechanism underlying the development of treatment resistance to proteasome inhibitors in multiple myeloma. Surprisingly, the mechanism also was linked to a…

Cancer Treatment Centers of America (CTCA) recently began enrolling patients with cancer for the clinical trial study TAPUR — Targeted Agent and Profiling Utilization Registry.